In some @entity1 , symptoms of @entity2023 can be severe and therefore rapid relief is required. There are many treatment options for @entity2023 but @entity112 H1 blockers and topical corticosteroids represent the first-line treatment. Although the latter drugs are usually very effective on nasal symptoms, their onset of action is around 24 h. Thus drugs that are more rapidly effective are of interest. Recently 400 French specialists (in Allergy, ENT and Pneumology) met together to define the criteria for selecting a drug for the treatment of @entity2490 . Twelve criteria were proposed and rapid onset of action (less than 24 h) was among the foremost designated criteria. In the first trial, a comparison of @entity54038 (10 mg once daily [od]) with @entity14746 (10 mg od) and placebo was carried out in the management of @entity56 ( @entity56 ) with special focus on onset of action. A total of 375 @entity1 were included in this European multicentric, randomized, parallel group and placebo-controlled study. By comparison to placebo, both @entity14746 and @entity54038 reduced significantly nasal and ocular symptoms during the 28-day follow-up trial. The percentage of responders ranged from 40% in the placebo group to 55% in the @entity54038 group and 53% in the @entity14746 group. Both active drugs were effective from the first intake with a rapid onset within 2 h. However, @entity54038 was more rapidly and more profoundly effective than @entity14746 during the first 12 h. A second trial included 257 @entity1 suffering from @entity56 ( @entity56 ) in a 4-week double-blind placebo-controlled multicentric study. During the study, @entity1 recorded, using a diary card, ocular and nasal symptoms, including nasal blockage. The mean values of nasal score between day 1, 14 and 28 in the @entity54038 group were statistically significantly lower than those in the placebo group. The mean values of ocular score showed a statistical difference in recordings between day 1 and day 14 in favour of the @entity54038 group. @entity54038 was an effective drug both in @entity56 and @entity56 with a rapid onset of action. @entity54038 relieved symptoms more effectively than @entity14746 ( @entity56 ) and placebo ( @entity56 and @entity56 ) at the beginning of treatment.

Rapid symptom relief in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis'] @entity2490 :: ('MESH:D012220', 'Disease') :: ['rhinitis'] @entity56 :: ('MESH:D004342', 'Disease') :: ['seasonal allergic rhino-conjunctivitis', 'perennial allergic rhino-conjunctivitis', 'SAR', 'PAR'] @entity14746 :: ('MESH:D017332', 'Chemical') :: ['cetirizine'] @entity112 :: ('MESH:D006632', 'Chemical') :: ['histamine'] @entity54038 :: ('MESH:C076170', 'Chemical') :: ['mizolastine', 'Mizolastine']
@entity2490 :: (MESH:D012220,Disease) :: ['rhinitis']
